

6th Annual

IMMUNO-ONCOLOGY 360°

February 26-28, 2020 | Crowne Plaza Times Square, New York City, NY



Executive Sponsors



Supporting and Educational Partners



DAY ONE - WEDNESDAY, FEBRUARY 26, 2020**Day One includes the following topics:**

- ✦ Discovery/Preclinical Science
- ✦ Imaging Aspects
- ✦ Clinical Operations
- ✦ Next Generation Bispecifics

7:30 am**Registration****8:15 am****Co-Chair's Opening Remarks****Axel Hoos, MD, PhD***SVP, Oncology R&D, GSK***James Gulley, MD, PhD***Chief, Genitourinary Malignancies Branch, Director, Medical Oncology Service, Center for Cancer Research, National Cancer Institute, NIH***OPENING KEYNOTE****8:25 am****T Cell Therapy for Cancer****Carl June, MD***Richard W. Vague Professor in Immunotherapy at the Department of Pathology and Laboratory Medicine; Director, Center for Cellular Immunotherapies at the Perelman School of Medicine; Director, Parker Institute for Cancer Immunotherapy, University of Pennsylvania***DISCOVERY & PRECLINICAL SCIENCE PLENARY SESSION****8:55 am****Overview Talk on the Biology of Targeted Cytokine Delivery****Pablo Umaña, PhD***Head, Cancer Immunotherapy Discovery, Pharma Research and Early Development, Roche***9:15 am****Safely Targeting TGF Beta, Challenges and Opportunities****Rik Derynck, PhD***Professor, Departments of Cell/Tissue Biology and Anatomy, University of California San Francisco***9:35 am****Grand Opening of the Networking Café & Exhibit Rooms**

- ✦ Breakfast
- ✦ Partnering Tables
- ✦ Meet the Exhibitors
- ✦ Networking

10:20 am**Updates on IL-15****John Desjarlais, PhD***SVP, Research & CSO, Xencor***10:40 am****Off-the-Shelf Cell-based Cancer Immunotherapy for Mass Production of Precisely Engineered Allogeneic T Cell and NK Cell Products Derived from (iPSC) Master Cell Lines**

This talk will discuss and outline the roadmap for development of off-the-shelf cell therapies based on engineered T cells and natural killer (NK) cells derived from induced pluripotent stem cell (iPSC) master cell lines. The presentation will highlight single cell engineering for precise editing of unique genetic input, creation of clonal master cell banks for the renewable source of consistent and low-cost large scale manufacturing, and the anti-tumor efficacy of engineered T and NK cells designed with unique attributes to improve safety and potency.

Bahram (Bob) Valamehr, PhD*Chief Development Officer, Fate Therapeutics***10:55 am****Epigenetic Priming of the Tumor Microenvironment Synergizes with NHS-IL12 to Promote Effective Tumor Control****Sofia Gameiro, PhD***Staff Scientist & Head, Immunomodulation Group, Laboratory of Tumor Immunology and Biology, National Cancer Institute***11:15 am****Immune Landscape Signatures for Tumor Microenvironment Characterization and Therapy Response****Patrice Hugo, PhD***CSO, Q² Solutions***11:30 am****Neoantigen Vaccine Processing and Algorithms for Predicting Peptide Structure****Roman Yelensky, PhD***EVP & Chief Technology Officer, Gritstone Oncology***11:50 am****Payload Oncolytic Virus: Viral Delivery of Genes that Allow for Local Production of Immune Modulators****12:10 pm****Lunch & Partnering Meetings****1:10 - 3:40 pm****Two Track Choices****Track A - Imaging Aspects****Track B - Clinical Operations**

Track A: Imaging Aspects**1:10 pm****Updates on Avelumab Study Comparing Investigator Assessments Using RECIST 1.1 and Immune RECIST****S. Peter Eggleton, MD, FFPM***Medical Director, GCDG Oncology, Merck KGaA***1:30 pm****IO Criteria in the Brain**

This talk will discuss the immunotherapy response assessment for neuro-oncology (iRANO) criteria, pros and cons along with case studies and examples.

Oliver Bohnsack, MD, PhD*VP, Scientific and Medical Services, Medical Imaging, Head of Oncology, Parexel***Manuela Lesch***Director, Scientific and Medical Services, Parexel Informatics***1:50 pm****Inter-tumor Growth Dynamics Signature Differences in IO****Dean Bottino, PhD***Senior Scientific Director, Clinical Translational Modeling & Simulation Leader, Takeda***2:10 pm****New Imaging Technologies for Evaluation of Immune Response****Ron Korn, MD, PhD***Founder, Chairman and CMO, Imaging Endpoints***2:30 pm****LN Enlargement as a Predictor of Immune Response****2:50 pm****Using Technology to Address Challenges in Implementation & Monitoring of IO Criteria****Amit Vasanji, PhD***Chief Technology Officer, Oncology, ERT***3:05 pm****Panel: Innovations & Novel Approaches in IO Imaging & Assessing Responses**

Moderated by:

Annette Schmid, PhD*Senior Scientific Director, Clinical Imaging Scientist, Takeda Pharmaceuticals*

Panelists:

Gregory Goldmacher, MD, PhD*Executive Director, Translational Biomarkers, Head of Clinical Imaging, Merck***S. Peter Eggleton, MD, FFPM***Medical Director, GCDG Oncology, Merck KGaA***Ron Korn, MD, PhD***Founder, Chairman and CMO, Imaging Endpoints***Track 2: Clinical Operations****1:10 pm****Operational Strategy in T cell Engagers / Bispecific Studies**

♦ Clinical Trial Design

♦ Landscape, Feasibility & Recruitment

♦ Managing toxicities in Bispecifics

♦ Challenges & Opportunities

Iris Sisson*Head of Clinical Operations, IGM Biosciences***1:30 pm****CRO Case Study****1:50 pm****Operational Dynamics of Implementing & Managing Basket Trials**

♦ What are the operational complexities of basket trials? How do they differ from standard IO trials?

♦ How do you identify the right institutions who can handle basket trials? What goes into that decision making?

♦ How do you set up your protocol in an open ended way so that you can add a cohort or make adjustments based on signals you received?

♦ How do you set up your database to be able to manage all the different tumor types and different types of case port forms.

Millie Shultz*Senior Director, Regional Clinical Trial Operations, Seattle Genetics***2:10 pm****CRO Case Study****2:30 pm****The Mechanics of Designing and Executing IO Studies in Collaboration with Site Partners to Increase Efficiencies and Provide Greater Access to Clinical Trials**

Panelists:

Andy Lee*SVP, Head of Global Clinical Trial Operations, Merck***Archana Sah***Chair, Oncology Board, Society for Clinical Research Sites***Beth Metzheiser***Head of Clinical Operations, Hematology and CRO Collaborations, BMS*Speaker TBD, **Covance**Speaker TBD, **Medidata**

3:40 pm

Afternoon Networking Break, Meet the Exhibitors, Partnering Meetings & Refreshments

NEXT GENERATION BISPECIFICS PLENARY SESSION

4:25 pm

Bispecific Antibodies in Cancer Immunotherapy

- ✦ Bispecific Antibodies overview (history, latest developments in Ab engineering, bispecific vs CAR-Ts)
- ✦ An emerging class of immunotherapeutics: CD3x bispecifics in hematologic malignancies
- ✦ A novel platform of costimulatory bispecifics antibodies to enhance the anti-tumor efficacy of existing therapies

Dimitris Skokos, PhD

Director, Immunology & Inflammation, Regeneron Pharmaceuticals

4:45 pm

Cytokine Release Syndrome with Bispecifics and CART

This talk will also cover the efficacy, toxicity and ways to tackle toxicity.

Stephan Grupp, MD, PhD

Chief, Cellular Therapy and Transplant Section, Children's Hospital Of Pennsylvania (CHOP)

5:05 pm

T cell Therapeutics to Treat Hematological Malignancies and Solid Tumors

T cell therapeutics have demonstrated clinical benefit in hematological malignancies and there is growing evidence of activity in solid tumors. This presentation will describe key findings from recent trials along with observations from nonclinical studies that inform on mechanism of action and approaches to address clinically-observed challenges.

Tara Arvedson, PhD

Executive Director, Oncology Research, Amgen

5:25 pm

Cancer Immunotherapy Debate: Bispecifics vs Cell Therapies

Carl June, MD

Richard W. Vague Professor in Immunotherapy at the Department of Pathology and Laboratory Medicine; Director, Center for Cellular Immunotherapies at the Perelman School of Medicine; Director, Parker Institute for Cancer Immunotherapy, University of Pennsylvania

vs

Daniel Chen, MD, PhD

Chief Medical Officer, IGM Biosciences

5:45 pm

Next Generation Bispecifics in Solid Tumors

- ✦ What is happening in hematology bispecific programs compared to solid tumor bispecific programs?
- ✦ What do bispecifics look like in solid tumors and what is driving efficacy?
- ✦ What's hindering efficacy in solid tumors compared to hematology?
- ✦ How can we improve on it?
- ✦ What should we be doing on the next generation bispecifics?

Moderated by:

Priti Hedge, PhD

Chief Scientific Officer, Foundation Medicine

Panelists:

Dimitris Skokos, PhD

Director, Immunology & Inflammation, Regeneron Pharmaceuticals

Tara Arvedson, PhD

Executive Director, Oncology Research, Amgen

David Schaer, PhD

Director, Translational Oncology Lead, Pfizer

Pablo Umaña, PhD

Head, Cancer Immunotherapy Discovery, Pharma Research and Early Development, Roche

6:30 pm

End of Day One

DAY TWO - THURSDAY, FEBRUARY 27, 2020

Day Two includes the following topics:

- ✦ Business Developments
- ✦ IO Novel Technologies
- ✦ Translational Science and Biomarkers
- ✦ IO Imaging Aspects
- ✦ Cell & Gene Therapy Day

7:45 am

Registration

8:15 am

Co-Chair's Opening Remarks

Ian McCaffery, PhD

VP, Oncology Translational Research, Janssen R&D

Andrew Baum, MD

Head of Global Healthcare, Managing Director, Equity Research, Citi

OPENING KEYNOTE

8:25 am

Arie Belldegrun, MD, FACS

Executive Chairman & Co-founder, Allogene

FINANCIAL KEYNOTE

8:50 am

Evaluation and Forecast of the IO Space

Andrew Baum, MD

Head of Global Healthcare, Managing Director, Equity Research, Citi

9:15 am

Opening of the Networking Café & Exhibit Rooms

- ✦ Breakfast
- ✦ Partnering Tables / Networking
- ✦ Meet the Exhibitors

9:55 am - 6:15 pm

Choice between Business Developments, Translational Science & Emerging Biomarkers and Cell/Gene Therapy Day

TRACK A: Business Developments Plenary Session	TRACK B: Cell & Gene Therapy Day
Chaired by: Andrew Baum, MD , Head of Global Healthcare, Managing Director, Equity Research, Citi	Chaired by: Aiman Shalabi, PharmD , VP R&D, Cell and Gene Therapies, GSK
9:55 – 10:15 am The Endpoints News Report John Carroll , Editor-in-Chief, Endpoints News	9:55 – 10:40 am Landscape and Evolution of the Marketplace Led by: Brad Loncor , CEO, Loncor Investments
10:15 – 11:00 am What Do Next Generation of Immunotherapies Need to Look Like to Move the Needle? Led by: Jeffrey Bockman, PhD , EVP & Head, Oncology Practice, Cello Health BioConsulting Panelists: Charles Drake, MD, PhD , Director Genitourinary Oncology Co-Director Immunotherapy Associate Director, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center Asthika Goonewardene, MBA , Managing Director, Senior Biotech Analyst, SunTrust Robinson Humphrey Bibash Mukhopadhyay, PhD , Principal, New Enterprise Associates	Panelists: Vanessa Lucey, PhD , Director, CRI Venture Fund and Clinical Accelerator, Cancer Research Institute Janet Lynch Lambert , CEO, Alliance for Regenerative Medicine Adrian McKemey, PhD , Managing Director and Head of R&D Strategy Solutions, IQVIA
IO Novel Technologies This session showcases companies that have technologies and solutions that will help stakeholders in the IO field advance developments that provide treatment for cancer patients.	10:40 – 11:35 am Innovation Hour: New Scientific Frontiers in Cell Therapies for Solid Tumors Led by: Crystal Mackall, MD , Professor of Pediatrics and Medicine; Director, Stanford Center for Cancer Cell Therapy; Director, Parker Institute for Cancer Immunotherapy at Stanford; Associate Director, Stanford Cancer Institute, Stanford University School of Medicine
11:00 - 11:50 am Participating Companies: ♦ ALMAC ♦ Axiom Healthcare Strategies	Cell Therapy Pivotal Pharma Developments for Solid Tumors
Translational Science & Biomarkers	11:35 – 11:55 am TILS Targeting Individual Tumor Mutations Stephanie Goff, MD , Associate Research Physician, Surgery Branch, National Cancer Institute, NIH
11:50 am – 12:10 pm Suppressive Cells in the Tumor Microenvironment Charles Drake, MD, PhD , Director Genitourinary Oncology Co-Director Immunotherapy Associate Director, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center	11:55 am – 12:15 pm Update on NY-ESO Aiman Shalabi, PharmD , VP R&D, Cell and Gene Therapies, GSK
12:10 – 12:30 pm Mitra Biotech Case Study	12:15 – 12:30 pm Reserved Talk
12:30 – 1:30 pm Lunch & Partnering Meetings	12:30 – 1:30 pm Lunch & Partnering Meetings
1:30 – 1:50 pm Cancer Immunotherapy Debate: Insitu Vaccinations vs Systemic Neo-Epitope Vaccinations Charles Drake, MD, PhD , Director Genitourinary Oncology Co-Director Immunotherapy Associate Director, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center	1:30 – 1:50 pm Virus Specific T Cells as Platform for Solid Tumor Immunotherapy The ability to simultaneously monitor changes in multiple immune parameters holds great discriminatory and instructive power for the purpose of biomarker validation and mechanistic target discovery. In the case of Virus Specific T cell therapy for solid tumors, an examination of the systemic, cellular and local immune environment during the course of treatment has yielded a series of predictive biomarkers correlating with immunogenicity, response to therapy and overall survival on trial. An analysis of antigen specific T-cells have identified anti-viral responses with positive prognostic value. Differences in the immunosuppressive state of the patient's activated regulatory T-cells (Tregs) and the expansion or contraction of the myeloid-derived suppressor cell (MDSC) compartment, point to a mechanism of action for the therapy. John Connolly, PhD , Chief Scientific Officer, Tessa Therapeutics Ltd
1:50 – 2:10 pm New Biomarkers for I-O Efficacy Jeff Weber, MD, PhD , Deputy Director, Perlmutter Cancer Center; Co-Director, Melanoma Program & Head of Experimental Therapeutics, NYU Langone Medical Center	

TRACK A: Business Developments Plenary Session	TRACK B: Cell & Gene Therapy Day
2:10 – 2:30 pm A New Generation of Multidimensional Biomarkers for Immune Composition and Cell State Fueled by RNA Models ♦ Why legacy single-analyte tools have hindered precision medicine ♦ How multidimensional models can be built and leveraged for immune profiling; including cell composition, state (e.g. exhaustion), and biomarker discovery ♦ Translating tools from the single-laboratory setting to a decentralized model Jarret Glasscock, PhD, CEO, Cofactor Genomics	1:50 – 2:05 pm Evidence-based Accelerators for Early Phase IO Clinical Development How can you use innovation and calculated risk to accelerate development of cell therapies? In this talk, IQVIA discusses modeling of IO data to develop new types of strategies vs. modeling strategies to develop new types of evidence. Lessons learned from early cell therapy entrants on finding, recruiting and following the ‘right’ patients will also be presented. Chris Learn, PhD, Senior Therapeutics Strategy Director, Cell and Gene Therapy, IQVIA
2:30 – 2:50 pm Reserved Talk	2:05 – 2:25pm Current and Future Innovations Toward GMP Manufacturing of CAR and TCR Engineered T cells Michael Paglia, VP, CMC Operations, ElevateBio
2:50 – 3:05 pm Translational Science Driving Combinatorial Strategies Chris Boshoff, FRCP, FMedSci, PhD, Chief Development Officer, Pfizer Oncology	2:25 – 2:40 pm Reserved Talk
3:05 – 3:25 pm Reserved Talk	2:40 – 3:25 pm Panel: Evolution of Regulatory Policy For Cell/Gene Therapy Moderator: Peter Marks, MD, PhD, Director, Center for Biologics Evaluation and Research (CBER), FDA Panelists: Jeff Allen, PhD, President & CEO, Friends of Cancer Research Anne Chew, PhD, Executive Deputy Director, Center for Cellular Immunotherapies, University of Pennsylvania Additional Panelists TBD
3:25 – 4:05 pm Afternoon Networking Break & Partnering Meetings, Refreshments	3:25 – 4:05 pm Afternoon Networking Break & Partnering Meetings, Refreshments
4:05 – 4:25 pm TMB and PDL1: The Next Chapter This talk will briefly review how TMB entered the conversation in IO, followed by a review of recent data on TMB and PD-L1 and their potential implications for next steps in patient treatment and study designs. Alexandra Snyder, MD, Head, Translational Oncology / Executive Director, Oncology Early Development, Merck Research Labs	Moving Beyond Pharma: New Collaborative Development Paradigms for Cell Therapies
4:25 – 4:40 pm Reserved Talk	4:05 – 4:15 pm Master Protocol for Cell/ Gene Therapies and Parker Institutes Efforts/Innovations in Cell Therapy Ramy Ibrahim, MD, Chief Medical Officer and VP, Clinical Development, Parker Institute for Cancer Immunotherapy
4:40 – 4:55 pm Reserved Talk	4:15 – 4:25 pm Unlocking Trapped Innovation in Cell, Gene Therapy & Regenerative Medicine Mitch Finer, PhD, CSO, President and Executive Partner, ElevateBio
4:55 – 5:45 pm Panel: Mechanisms and Biomarkers of Resistance in the Era of IO Combination Therapy Moderated by: Priti Hedge, PhD, Chief Scientific Officer, Foundation Medicine	4:25 – 4:35 pm Cancer Therapy Evaluation Program Innovations in Cell Therapy (CTEP) Elad Sharon, MD, Senior Investigator, Cancer Therapy Evaluation Program (CTEP), National Cancer Institute
5:45 pm End of Day Two	4:35 – 4:45 pm Canadian Cancer Trials Group (CCTG) Speaker TBD
6:00 pm 6th Annual Networking Reception	

TRACK B: Cell & Gene Therapy Day

4:45 – 5:15 pm

Panel: New Collaborative Development Paradigms for Cell Therapies

Led by:

Ramy Ibrahim, MD, Chief Medical Officer and VP, Clinical Development, **Parker Institute for Cancer Immunotherapy**

Panelists:

Mitch Finer, PhD, CSO, President and Executive Partner, **ElevateBio****Elad Sharon, MD**, Senior Investigator, Cancer Therapy Evaluation Program (CTEP), **National Cancer Institute**

Cell & Gene Therapy Debates

5:15 – 5:35 pm

Combinations with Checkpoints**Christina Coughlin, MD, PhD**, EVP & CMO, **Tmunity** vs**Saul Priceman, PhD**, Assistant Professor, Department of Hematology & Hematopoietic Cell Transplantation, **City of Hope**

5:35 – 5:55 pm

Bedside Manufacturing vs Centralized Manufacturing**Boro Dropulić, PhD**, Chief Science Officer & General Manager, **Lentigen**

6:00 pm

6th Annual Networking Reception

DAY THREE - FRIDAY, FEBRUARY 28, 2020

Day Three includes the following topics:

- ✦ AI & Machine Learning
- ✦ IO Clinical Developments

7:45 am

Registration

8:15 am

Co-Chair's Opening Remarks

Daniel Chen, MD, PhDChief Medical Officer, **IGM Biosciences****Jacqueline Karmel**Group Global Scientific Director / Chair, imCORE Executive Committee, **Roche**

PATIENT KEYNOTE FIRESIDE CHAT

8:25 am

Moderator:

Cindy Geoghegan

Patient Advocate

VIP Patient Guest:

Jane Perlmutter, PhD

Cancer Survivor and Advocate

AI & MACHINE LEARNING PLENARY SESSION

8:55 am

AI & Machine Learning in R&D

This talk will provide an overview of how AI & Machine Learning is being used in drug discovery and development and how it is applicable to the cancer immunotherapy field.

Kim Branson, PhDSVP, Global Head, Artificial Intelligence and Machine Learning, **GSK**

9:15 am

Machine Learning for Tumor and Cell Segmentation and Cell Classification within the Tumor Microenvironment

Machine/Deep learning methods for the analysis of the tumor microenvironment can greatly aid oncological research through the automation of largely manual tasks. Using their proprietary analytics workflow, NeoGenomics presents results for tumor segmentation, cell segmentation and classification for CD8 and PD-L1, and spatial analytics, which will provide attendees with a deeper understanding of the effect that automation has on analytics precision and time-saving, and how it enables the generation of large volumes of data that were not possible just a couple of years ago.

Máté Levente Nagy, PhDSenior Scientist & Technical Lead, Computational Biology, **NeoGenomics Laboratories, Inc**

9:35 am

Opening of the Networking Café & Exhibit Rooms

- ✦ Breakfast
- ✦ Partnering Tables / Networking
- ✦ Meet the Exhibitors

10:20 am

Using Machine Learning to Extract Meaningful Insights for Cancer Immunotherapy

Led by:

Matthew Albert, MD, PhDVP, Immunology & Infectious Diseases, **Insitro**

Panelists:

Kim Branson, PhDSVP, Global Head, Artificial Intelligence and Machine Learning, **GSK****Martin Stumpe, PhD**SVP, Data Science, **Tempus**

Additional Panelists TBD

IO CLINICAL DEVELOPMENTS

11:00 am

Next Generation Checkpoints in the Clinic

This talk gives a comprehensive assessment on IDO, A2A, TGF, LAG3, TIM3 and other antagonist antibodies.

Addressing:

- ✦ What are they really delivering?
- ✦ Why aren't they showing more?
- ✦ Are they likely to be effective therapies in combination with pd1 or are they going to be met?

11:20 am**Emerging Agonist Antibodies**

This talk provides a summary of agonist antibodies such as OX40, CD27, GITR, 41BB, CD40 – and addresses the differences in the biology, what it is showing vs where it is not showing as much as we would have liked and why.

Andy Weinberg, PhD*CSO, President, AgonOx***11:50 am****Clinical Development of ICOS Agonist Antibodies****Axel Hoos, MD, PhD***SVP, Oncology R&D, GSK***12:10 pm****Clinical Review of TGF Beta Trap PDL1 Bispecific Antibody****Olaf Christensen, MD***Vice President, Global Development and R&D, Head, TGF-beta TRAP, EMD Serono***12:30 pm****Lunch on Own & Partnering Meetings****1:30 pm****Update on Merck's IO Clinical Developments****Roy Baynes, MD, PhD***SVP & Head, Global Clinical Development, Chief Medical Officer, Merck Research Laboratories***1:50 pm****Novel Approaches to IO-IO Combinations****Lee James, MD, PhD***Clinical Program Lead, Early Clinical Development, Oncology, BMS***2:10 pm****Advancements in IO Combination Trial Platforms**

Some of the newer combination platforms are producing data that reflects combinations with PD1/PDL1 inhibitors. We now have a better understanding of actual data and how signals come out of a trial like this. We will feature 10-15 minute talks that include combination platforms such as MORPHEUS, FRACTION, etc.

4:00 pm**Conference Concludes**